Earnings Summary

Atara Biotherapeutics Inc’s revenue jumped 1823.98% since last year same period to $4.25Mn in the Q4 2023. On a quarterly growth basis, Atara Biotherapeutics Inc has generated 98.88% jump in its revenue since last 3-months.

Atara Biotherapeutics Inc’s net profit jumped 18.94% since last year same period to $-60.45Mn in the Q4 2023. On a quarterly growth basis, Atara Biotherapeutics Inc has generated 13.39% jump in its net profits since last 3-months.

Atara Biotherapeutics Inc’s net profit margin jumped 95.79% since last year same period to -1421.68% in the Q4 2023. On a quarterly growth basis, Atara Biotherapeutics Inc has generated 56.45% jump in its net profit margins since last 3-months.

Atara Biotherapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.26 - a 45.83% jump from last quarter’s estimates.

Atara Biotherapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.26.

Atara Biotherapeutics Inc’s earning per share (EPS) jumped 22.22% since last year same period to -0.56 in the Q4 2023. This indicates that the Atara Biotherapeutics Inc has generated 22.22% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Atara Biotherapeutics Inc’s return on assets (ROA) stands at -0.62.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Atara Biotherapeutics Inc’s return on equity (ROE) stands at -20.15.